JP2018522049A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522049A5 JP2018522049A5 JP2018505714A JP2018505714A JP2018522049A5 JP 2018522049 A5 JP2018522049 A5 JP 2018522049A5 JP 2018505714 A JP2018505714 A JP 2018505714A JP 2018505714 A JP2018505714 A JP 2018505714A JP 2018522049 A5 JP2018522049 A5 JP 2018522049A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrate
- pharmaceutically acceptable
- acceptable salt
- formula
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562200549P | 2015-08-03 | 2015-08-03 | |
| US201562200545P | 2015-08-03 | 2015-08-03 | |
| US201562200556P | 2015-08-03 | 2015-08-03 | |
| US62/200,549 | 2015-08-03 | ||
| US62/200,556 | 2015-08-03 | ||
| US62/200,545 | 2015-08-03 | ||
| US201562201009P | 2015-08-04 | 2015-08-04 | |
| US62/201,009 | 2015-08-04 | ||
| US201562235102P | 2015-09-30 | 2015-09-30 | |
| US62/235,102 | 2015-09-30 | ||
| PCT/US2016/043676 WO2017023584A1 (en) | 2015-08-03 | 2016-07-22 | Combination therapies for treating cancers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020171578A Division JP2021001237A (ja) | 2015-08-03 | 2020-10-09 | がん処置のための組み合わせ療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522049A JP2018522049A (ja) | 2018-08-09 |
| JP2018522049A5 true JP2018522049A5 (cg-RX-API-DMAC7.html) | 2019-09-05 |
| JP6815383B2 JP6815383B2 (ja) | 2021-01-20 |
Family
ID=56555867
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018505714A Expired - Fee Related JP6815383B2 (ja) | 2015-08-03 | 2016-07-22 | がん処置のための組み合わせ療法 |
| JP2020171578A Pending JP2021001237A (ja) | 2015-08-03 | 2020-10-09 | がん処置のための組み合わせ療法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020171578A Pending JP2021001237A (ja) | 2015-08-03 | 2020-10-09 | がん処置のための組み合わせ療法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20180207164A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3331531A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6815383B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016304172A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2994265A1 (cg-RX-API-DMAC7.html) |
| HK (1) | HK1255939A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW201717953A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017023584A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110772521A (zh) * | 2018-07-31 | 2020-02-11 | 苏州亚盛药业有限公司 | Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途 |
| AU2019387508A1 (en) * | 2018-11-30 | 2021-06-10 | Aptose Biosciences Inc. | Combination therapy with 2,3-dihydro-isoindole-1-one compounds and methods for treating patients with various mutations |
| WO2021157650A1 (ja) * | 2020-02-05 | 2021-08-12 | カルナバイオサイエンス株式会社 | 抗がん剤組成物 |
| WO2024037910A1 (en) * | 2022-08-17 | 2024-02-22 | Institut National de la Santé et de la Recherche Médicale | Syk inhibitors for use in the treatment of cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6408993B2 (ja) * | 2012-09-07 | 2018-10-17 | ジェネンテック， インコーポレイテッド | タイプＩＩ抗ＣＤ２０抗体と選択的Ｂｃｌ−２インヒビターの併用療法 |
| MX369503B (es) * | 2013-04-08 | 2019-11-11 | Pharmacyclics Llc | Combinaciones que comprenden ibrutinib y abt-199 para tratar trastornos proliferativos de células b y métodos de uso de las mismas. |
| EP3003309B1 (en) * | 2013-05-30 | 2020-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| CN114632158A (zh) * | 2013-11-07 | 2022-06-17 | 豪夫迈·罗氏有限公司 | 抗cd20抗体与btk抑制剂的组合疗法 |
| UY35898A (es) * | 2013-12-23 | 2015-07-31 | Gilead Sciences Inc | ?compuestos inhibidores de syk y composiciones que los comprenden?. |
| HRP20220738T1 (hr) * | 2014-08-11 | 2022-08-19 | Acerta Pharma B.V. | Terapijske kombinacije inhibitora btk, inhibitora pd-1 i/ili inhibitora pd-l1 |
| PT3179991T (pt) * | 2014-08-11 | 2021-11-26 | Acerta Pharma Bv | Combinações terapêuticas de um inibidor de btk e um inibidor de bcl-2 |
| JP6785804B2 (ja) * | 2015-06-23 | 2020-11-18 | ギリアド サイエンシズ， インコーポレイテッド | Ｂ細胞悪性腫瘍を治療するための組合せ療法 |
-
2016
- 2016-07-22 CA CA2994265A patent/CA2994265A1/en not_active Abandoned
- 2016-07-22 HK HK18115008.8A patent/HK1255939A1/zh unknown
- 2016-07-22 EP EP16745381.0A patent/EP3331531A1/en not_active Withdrawn
- 2016-07-22 AU AU2016304172A patent/AU2016304172A1/en not_active Abandoned
- 2016-07-22 US US15/749,222 patent/US20180207164A1/en not_active Abandoned
- 2016-07-22 WO PCT/US2016/043676 patent/WO2017023584A1/en not_active Ceased
- 2016-07-22 JP JP2018505714A patent/JP6815383B2/ja not_active Expired - Fee Related
- 2016-07-22 TW TW105123357A patent/TW201717953A/zh unknown
-
2020
- 2020-10-09 JP JP2020171578A patent/JP2021001237A/ja active Pending